GastroCE
CLINICAL CASECME

Eosinophilic Esophagitis: Updated Guidelines and Therapeutic Advances to Manage an Evolving Disease

Author(s)/Faculty: Ikuo Hirano, MD; Mirna Chehade, MD MPH; Evan S. Dellon, MD MPH
Release Date: 11/30/2020Expiration Date: 11/29/2021
Credit Type: CMENumber of Credits: 1.5
Content Type: VideoProvider:
Eosinophilic esophagitis (EoE) is a chronic disorder, characterized by symptoms of esophageal dysfunction due to esophageal inflammation from increased numbers of intraepithelial eosinophils, that affects both pediatric and adult patients. EoE is a relatively new disease caused by a T-helper type 2 cell response to food antigens in contact with the esophageal mucosa. The goal of treatment is to control esophageal eosinophilia and inflammation, which trigger the symptoms and fibrotic processes in the esophagus. Currently, no drugs are approved by the US Food and Drug Administration for the treatment of EoE. However, topical corticosteroids and proton pump inhibitors have been shown to be effective treatment modalities for patients with confirmed EoE. New 2020 guidelines released by the American Gastroenterological Association strongly recommend use of topical steroids as the first-line treatment for children and adults with EoE over no treatment at all. Budesonide oral suspension is a topically active, oral, viscous formulation of budesonide, created specifically as an investigational treatment for EoE. In this, case-based educational activity, expert faculty provide guidance on the criteria for diagnosing EoE as well as review the updated guideline recommendations and treatment options for the optimal management of patients with EoE.